Patents Examined by Jonathan S Lau
  • Patent number: 11324769
    Abstract: The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: May 10, 2022
    Assignee: Astrocyte Pharmaceuticals, Inc.
    Inventors: Russell Birch Poe, David T. Jonaitis, Lisa Michelle Grove
  • Patent number: 11326195
    Abstract: Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by ?-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 10, 2022
    Inventor: Gary B. Nickel
  • Patent number: 11311562
    Abstract: Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: April 26, 2022
    Assignee: ABBOTT LABORATORIES
    Inventors: Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen
  • Patent number: 11311644
    Abstract: A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: April 26, 2022
    Assignee: Medoderm GmbH
    Inventors: Rivelino Montenegro, Thomas Freier, Karsten Henco
  • Patent number: 11312740
    Abstract: The present invention relates to an industrially feasible and economically viable process for preparation of SGLT2 inhibitors of formula X in significantly high yield and purity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: April 26, 2022
    Assignee: PIRAMAL PHARMA LIMITED
    Inventors: Milind Gharpure, Sanjay Kumar Sharma, Sandesh Vishwasrao, Prasad Vichare, Dipak Varal
  • Patent number: 11299483
    Abstract: Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 12, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Douglas J. Dellinger, Joel Myerson, Brian Smart
  • Patent number: 11285137
    Abstract: Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 29, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Richard Kolesnick, Adriana Haimovitz-Friedman, Evis Sala, Zvi Fuks
  • Patent number: 11273161
    Abstract: Methods of diagnosing and treating autism spectrum disorders are provided.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 15, 2022
    Assignee: The Broad Institute, Inc.
    Inventors: Jon Madison, Jeffrey Cottrell
  • Patent number: 11266681
    Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Nate Larson, Robert G. Strickley
  • Patent number: 11266680
    Abstract: Pharmaceutical composition and their uses are disclosed, the composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the HDL cholesterol level.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: March 8, 2022
    Assignee: Roquette Freres
    Inventors: Marc Salome, Daniel Wils, Xavier Parissaux, Francois Mach, Fabrizio Montecucco
  • Patent number: 11248016
    Abstract: The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitising or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorder which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 15, 2022
    Assignee: THE UNIVERSITY OF NOTTINGHAM
    Inventors: Andrew Bottley, Christopher Hayes, Graham Seymour, Anna Grabowska, Philip Clarke
  • Patent number: 11246878
    Abstract: Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 15, 2022
    Assignee: B&H BIOTECHNOLOGIES, LLC
    Inventor: Huiru Wang
  • Patent number: 11246879
    Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 15, 2022
    Assignee: Tulai Therapeutics, Inc.
    Inventors: Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
  • Patent number: 11234998
    Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 1, 2022
    Assignee: Tricol Biomedical, Inc.
    Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
  • Patent number: 11225500
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 18, 2022
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • Patent number: 11208499
    Abstract: Water soluble, lipophilic starches are provided, which comprise a mixture of functionalized high and low molecular weight maltodextrin molecules. The starches may be formed by dispersing a granular starch in a liquid medium to form a slurry that is simultaneously cooked and subjected to enzyme hydrolysis. Following hydrolysis, the starch is functionalized with an organic acid anhydride reagent, such as octenylsuccinic anhydride. The organic acid anhydride substitution occurs randomly and at various locations within the maltodextrin molecules.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: December 28, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: Yong-Cheng Shi, Yanjie Bai, Zhenhua Sun
  • Patent number: 11207345
    Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: December 28, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Sho Funayama, Risa Nodera, Takahiro Hatanaka
  • Patent number: 11197932
    Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: December 14, 2021
    Assignee: The Regents of the University of California
    Inventors: Kathryn M. Camacho, Stefano Menegatti, Sunny Kumar, Douglas Vogus, Samir Mitragotri
  • Patent number: 11198704
    Abstract: A newly developed butane-tetraol-based amphiphilic compound, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, crystallizing or analyzing a membrane protein using the amphiphilic compound are provided. The butane-tetraol-based compound is found to have a central structure exhibiting chirality, and isomers of the compound have clearly different characteristics according to the stereochemistry of the central structure, thereby making it possible to select compounds suitable for the uses thereof. Also, the compound can be used to effectively extract a membrane protein, which has more various structures and characteristics than conventional compounds, from cell membranes and stably store the membrane protein in an aqueous solution for a long time, and thus analyze the function and structure of the membrane protein.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 14, 2021
    Assignee: Industry—University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Manabendra Das
  • Patent number: 11191274
    Abstract: Compositions are provided that have at least two of three active ingredients. The active ingredients maybe a salt having a cation N? C8-C6 alkanoyl-L di-basic amino acid —C1-C4 alkyl ester, a glycerol monoester of a fatty acid and a sugar ester of a fatty acid. The compositions are useful in methods of killing or inhibiting planktonic bacteria or fungi and bacteria or fungi embedded in a biofilm and prevention of biofilm formation on surfaces. The composition may further comprise a hydrogel and a benefit agent such as an antibiotic that can be solubilized by the hydrogel and supplied to the biofilm matrix by the active ingredients of the composition. Devices such as chronic wound coverings coated with the composition are also provided. Methods of preserving products with the composition are also provided.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: December 7, 2021
    Assignee: NEVADA NATURALS INC.
    Inventors: Anthony J. Sawyer, Richard F. Stockel